INVO Fertility Q4 2023 Earnings Report

INVO Fertility EPS Results

• Actual EPS: -$15.12
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

INVO Fertility Revenue Results

• Actual Revenue: $1.58 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

INVO Fertility Announcement Details

• Quarter: Q4 2023
• Date: 5/15/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

INVO Fertility (NASDAQ:IVF) (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation. By leveraging the natural conditions of the patient’s body, the INVOcell system aims to reduce the complexity, equipment requirements and cost associated with standard IVF lab procedures. INVO Fertility also provides complementary consumables and training programs to support fertility specialists in adopting its technology.

Originating in the early 2010s, INVO Fertility evolved from pioneering in-vivo fertilization research. The company secured U.S. Food and Drug Administration clearance for the INVOcell device in May 2015, marking a significant milestone that enabled commercial distribution. Since then, it has continued to expand its product portfolio and clinical support services to address the needs of fertility clinics and patients worldwide.

INVO Fertility markets and distributes its solutions across the United States and through a network of international partners in regions including Latin America, Europe, Asia-Pacific and the Middle East. The company collaborates with reproductive health professionals to provide hands-on training, technical assistance and ongoing clinical support, aiming to broaden access to cost-effective fertility treatment options globally.